Literature DB >> 28888784

Malignant ascites determine the transmesothelial invasion of ovarian cancer cells.

Justyna Mikuła-Pietrasik1, Paweł Uruski2, Sebastian Szubert3, Dariusz Szpurek4, Stefan Sajdak5, Andrzej Tykarski6, Krzysztof Książek7.   

Abstract

The exact role of malignant ascites in the development of intraperitoneal ovarian cancer metastases remains unclear. In this report we sought to establish if ascites can determine the efficiency of transmesothelial invasion of ovarian cancer cells, and, if so, whether the fluid generated by highly aggressive serous and undifferentiated tumors will promote the invasion more effectively than ascites from less aggressive clear cell and endometrioid cancers. The study showed that the invasion of ovarian cancer cells (SKOV-3 and primary cancer cells) across monolayered peritoneal mesothelial cells was elevated upon mesothelial cell exposure to fluid produced by serous and undifferentiated cancers, as compared with cells subjected to ascites from clear cell and endometrioid tumors. This effect coincided with decreased mesothelial expression of junctional proteins: connexin 43, E-cadherin, occludin, and desmoglein. Moreover, it was accompanied by transforming growth factor β1-dependent overproduction of reactive oxygen species by these cells. The activity of ascites from serous and undifferentiated tumors was mediated by p38 mitogen-activated protein kinase and nuclear factor κB. When the mesothelial cells were protected against oxidative stress, both deterioration of junctional proteins and intensification of cancer cell invasion in response to ascites from serous and undifferentiated tumors were effectively prevented. In conclusion, our findings indicate that the high aggressiveness of some histotypes of ovarian cancer may be related to the ability of malignant ascites generated by these cells to oxidative stress-dependent impairment of mesothelial cell integrity and the resulting increase in their transmesothelial invasion.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Intercellular junctions; Invasion; Malignant ascites; Ovarian cancer; Peritoneal mesothelium

Mesh:

Year:  2017        PMID: 28888784     DOI: 10.1016/j.biocel.2017.09.002

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  9 in total

Review 1.  The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.

Authors:  Sabrina J Ritch; Carlos M Telleria
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-28       Impact factor: 6.055

Review 2.  The untapped potential of ascites in ovarian cancer research and treatment.

Authors:  Caroline Elizabeth Ford; Bonnita Werner; Neville Frederick Hacker; Kristina Warton
Journal:  Br J Cancer       Date:  2020-05-08       Impact factor: 7.640

3.  Senescence-related deterioration of intercellular junctions in the peritoneal mesothelium promotes the transmesothelial invasion of ovarian cancer cells.

Authors:  Martyna Pakuła; Anna Witucka; Paweł Uruski; Artur Radziemski; Rafał Moszyński; Dariusz Szpurek; Konstantin Maksin; Aldona Woźniak; Stefan Sajdak; Andrzej Tykarski; Justyna Mikuła-Pietrasik; Krzysztof Książek
Journal:  Sci Rep       Date:  2019-05-20       Impact factor: 4.379

4.  ST3Gal3 confers paclitaxel‑mediated chemoresistance in ovarian cancer cells by attenuating caspase‑8/3 signaling.

Authors:  Xian Zhang; Xinying Yang; Ming Chen; Shaolie Zheng; Jinyuan Li; Shaoqiang Lin; Xiaoyu Wang
Journal:  Mol Med Rep       Date:  2019-09-26       Impact factor: 2.952

Review 5.  Insights into the Role of Oxidative Stress in Ovarian Cancer.

Authors:  Dan-Ni Ding; Liang-Zhen Xie; Ying Shen; Jia Li; Ying Guo; Yang Fu; Fang-Yuan Liu; Feng-Juan Han
Journal:  Oxid Med Cell Longev       Date:  2021-10-07       Impact factor: 6.543

6.  Hsa_circ_0000497 and hsa_circ_0000918 contributed to peritoneal metastasis of ovarian cancer via ascites.

Authors:  Ning Luo; Zubaidan Sulaiman; Chunyan Wang; Jinye Ding; Yingying Chen; Biting Liu; Zhongping Cheng; Shupeng Liu
Journal:  J Transl Med       Date:  2022-05-10       Impact factor: 5.531

Review 7.  Are antiangiogenics a good 'partner' for immunotherapy in ovarian cancer?

Authors:  Elena García-Martínez; Andres Redondo; Josep Maria Piulats; Analía Rodríguez; Antonio Casado
Journal:  Angiogenesis       Date:  2020-07-20       Impact factor: 9.596

8.  Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer.

Authors:  Yi Ding; Vera Labitzky; Karen Legler; Minyue Qi; Udo Schumacher; Barbara Schmalfeldt; Christine Stürken; Leticia Oliveira-Ferrer
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603

9.  Clinicopathologic factors associated with short-term survival in advanced epithelial ovarian cancer.

Authors:  Shuwei Zhou; Yao Liu; Wanchun Yin; Qianqian Liao; Quan Quan; Xiaoling Mu
Journal:  Transl Cancer Res       Date:  2019-10       Impact factor: 1.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.